Asuragen Signs Licensing Agreement With Focus Diagnostics
Asuragen, a fully integrated molecular diagnostics company, has granted Focus Diagnostics, the infectious disease diagnostics company of Quest Diagnostics, non-exclusive worldwide rights to incorporate Armored RNA technology into its in vitro molecular diagnostics products.
Under the terms of the agreement, Asuragen will develop and supply reagents for Focus Diagnostics in Asuragen’s QSR-compliant manufacturing facility.
Armored RNA is a technology jointly invented and developed by Asuragen and Cenetron Diagnostics for the packaging of RNA or DNA in bacteriophage coat proteins for protection and stabilization.
Matt Winkler, CEO and chief scientific officer of Asuragen, said: “We’re pleased Focus Diagnostics has chosen to incorporate Armored RNA into its molecular diagnostic assays. This agreement reinforces the continued evolution of Armored RNA standards and controls into an industry standard.”